Stonehouse Jon P 4

4 · BIOCRYST PHARMACEUTICALS INC · Filed Mar 3, 2026

AI-generated summary of this filing

Updated Mar 3, 2026

BIOCRYST (BCRX) Director Jon P. Stonehouse Exercises Options, Sells Shares

What Happened

Jon P. Stonehouse, a BIOCRYST Pharmaceuticals (BCRX) director, exercised 305,995 stock options and the resulting shares were sold back to the issuer on March 2, 2026. The sale generated about $2,643,797. He paid $985,304 to exercise those options (weighted exercise price $3.22), producing roughly $1.66M in gross proceeds before taxes and fees.
Separately, on February 27, 2026, Stonehouse received 421 shares (valued at $3,684) issued in lieu of 50% of his prorated quarterly cash board retainer.

Key Details

Transaction dates: Award on 2026-02-27; option exercise and sale on 2026-03-02. Form 4 filed on 2026-03-03 (timely).
Exercise: 305,995 options exercised at $3.22 per share (total cost $985,304).
Sale/disposition: 305,995 shares sold to the issuer at a weighted average price of $8.64 per share (total proceeds $2,643,797). Reported sale prices ranged $8.54–$8.81 (see footnote F3).
Award/grant: 421 shares issued in lieu of part of the cash retainer (footnote F1).
Plan/automation: The option exercise/sale was executed under a pre-established plan (10b5-1) adopted Nov 28, 2022 and modified in 2024; the filing notes the transactions occurred automatically and were not discretionary (footnote F2).
Shares owned after the transactions: not specified in the provided filing excerpt.

Context

This was an option exercise immediately followed by sale back to the issuer (a cashless-style outcome): options exercised (derivative -> common) and the common shares were disposed to the issuer the same day.
The 10b5-1 plan disclosure means the option conversion and sale were pre-planned and automated, which investors often view as reducing the significance of timing-based insider signals.
The small award of 421 shares was a compensation substitution (not a market purchase) and is routine for board members.

Form 4

Period: 2026-02-27

Director

Transactions

Award
Common Stock
[F1]
2026-02-27$8.75/sh+421$3,684→ 1,323,850 total
Exercise/Conversion
Common Stock
[F2]
2026-03-02$3.22/sh+305,995$985,304→ 1,629,845 total
Disposition to Issuer
Common Stock
[F2][F3]
2026-03-02$8.64/sh−305,995$2,643,797→ 1,323,850 total
Exercise/Conversion
Emp. Stock Option (Right to Buy)
[F2]
2026-03-02−305,995→ 0 total
Exercise: $3.22From: 2017-05-23Exp: 2026-05-23→ Common Stock (305,995 underlying)

Holdings

Footnotes (3)

[F1]Shares of Common Stock issued to the reporting person in lieu of 50% of the prorated quarterly cash Board Member retainer of $7,375.
[F2]This transaction was made pursuant to a plan adopted by the reporting person on November 28, 2022, as modified on May 13, 2024 and further modified on May 29, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The options were originally granted to the reporting person on May 23, 2016 and would have expired on May 23, 2026. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
[F3]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.54 to $8.81. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.

Signature

/s/ Alane P. Barnes, by power of attorney|2026-03-03

1 file